FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20240412E00175
1. Date of relevant event: 10/04/2024
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 06998
4. Name of listed corporation: Genor Biopharma Holdings Ltd. - B 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 512,532,554
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Guo
(Other names) Feng
10. Name of director (Chinese): 郭峰 
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
1303There has been a change in nature of your interest in the shares because:
you have exercised rights to the shares under equity derivatives
 
2101Beneficial owner
 
2101Beneficial owner
 		 4,442,416         
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position21,158,1084.13
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position21,158,1084.13
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2101Beneficial owner
Long position21,158,108
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
Long position
4105Unlisted derivatives - Physically settled
30/04/202030/04/2030USD0USD0.001  477,679
Long position
4105Unlisted derivatives - Physically settled
25/05/202325/05/2033HKD0HKD1.808  5,000,000
Long position
4105Unlisted derivatives - Physically settled
31/08/202331/08/2033HKD0HKD1.500  5,579,054
Long position
4105Unlisted derivatives - Physically settled
  HKD0    4,210,000
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
   
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
(private)Addresses of individuals are not displayed.
5102Beneficiary of a trust (other than a discretionary interest)
Long position5,891,375
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: On 10 April 2024, Dr. Guo exercised 4,442,416 share options under the Pre-IPO Share Option Plan that are held by MaplesFS (BVI) Limited on behalf of AKQM Partner Trust. The exercise price of these options is HK$0.00155.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 12/04/2024
(dd/mm/yyyy)